FI106862B - Menetelmä 4,13-dioksabisyklo[8.2.1]tridekenonijohdannaisten ja niiden välituotteiden valmistamiseksi - Google Patents

Menetelmä 4,13-dioksabisyklo[8.2.1]tridekenonijohdannaisten ja niiden välituotteiden valmistamiseksi Download PDF

Info

Publication number: FI106862B
Authority: FI; Finland
Prior art keywords: formula; methyl; dioxabicyclo; pentamethyl; dihydroxypent
Prior art date: 1992-01-07

Application number

FI930051A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI930051L (fi

FI930051A0 (fi

Inventor

Ulf Preuschoff

Christian Eeckhout

Dagmar Hoeltje

Original Assignee

Solvay Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-07

Filing date

1993-01-07

Publication date

2001-04-30

1993-01-07 Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh

1993-01-07 Publication of FI930051A0 publication Critical patent/FI930051A0/fi

1993-07-08 Publication of FI930051L publication Critical patent/FI930051L/fi

2001-04-30 Application granted granted Critical

2001-04-30 Publication of FI106862B publication Critical patent/FI106862B/fi

Links

238000000034 method Methods 0.000 title claims description 10
238000002360 preparation method Methods 0.000 title abstract description 12
230000008569 process Effects 0.000 title description 4
GRCGQCCTSGTTKZ-UHFFFAOYSA-N 7,13-dioxabicyclo[8.2.1]tridec-10-en-9-one Chemical class O=C1COCCCCCC2CC=C1O2 GRCGQCCTSGTTKZ-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 46
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 14
QBEKGNIWIHIMOM-UHFFFAOYSA-N tridec-12-en-5-one Chemical class CCCCC(=O)CCCCCCC=C QBEKGNIWIHIMOM-UHFFFAOYSA-N 0.000 claims description 11
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
230000000144 pharmacologic effect Effects 0.000 claims description 3
150000002431 hydrogen Chemical class 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 16
239000000047 product Substances 0.000 description 15
-1 sodium triacetoxyborohydride Chemical compound 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000000203 mixture Substances 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 13
239000000126 substance Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 12
229960003276 erythromycin Drugs 0.000 description 11
239000002904 solvent Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
239000002585 base Substances 0.000 description 10
210000001035 gastrointestinal tract Anatomy 0.000 description 10
229930006677 Erythromycin A Natural products 0.000 description 9
230000000694 effects Effects 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
102000002419 Motilin Human genes 0.000 description 6
101800002372 Motilin Proteins 0.000 description 6
102000057413 Motilin receptors Human genes 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000012043 crude product Substances 0.000 description 6
229910052736 halogen Inorganic materials 0.000 description 6
150000002367 halogens Chemical class 0.000 description 6
210000002784 stomach Anatomy 0.000 description 6
108700040483 Motilin receptors Proteins 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000030136 gastric emptying Effects 0.000 description 5
210000000111 lower esophageal sphincter Anatomy 0.000 description 5
239000003826 tablet Substances 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000908 ammonium hydroxide Substances 0.000 description 4
230000002183 duodenal effect Effects 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
230000005176 gastrointestinal motility Effects 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
210000005070 sphincter Anatomy 0.000 description 4
238000010626 work up procedure Methods 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
208000017228 Gastrointestinal motility disease Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000556 agonist Substances 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
150000008041 alkali metal carbonates Chemical class 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000011630 iodine Substances 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
238000007086 side reaction Methods 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
150000008044 alkali metal hydroxides Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
239000011539 homogenization buffer Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
150000002596 lactones Chemical group 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000010453 quartz Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
TXOOBKBDBNRQCF-QNPWSHAKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-6-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-(methylamino)oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](NC)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TXOOBKBDBNRQCF-QNPWSHAKSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
JFVYXJKGJMUGRG-KJPZRSJGSA-N Erythromycin a enol ether Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C2=C(C)C[C@](O2)(C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 JFVYXJKGJMUGRG-KJPZRSJGSA-N 0.000 description 1
208000001762 Gastric Dilatation Diseases 0.000 description 1
206010017999 Gastrointestinal pain Diseases 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000045576 Lactoperoxidases Human genes 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000006136 alcoholysis reaction Methods 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
IQDXNHZDRQHKEF-UHFFFAOYSA-N dialuminum;dicalcium;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[Ca+2].[Ca+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O IQDXNHZDRQHKEF-UHFFFAOYSA-N 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000030135 gastric motility Effects 0.000 description 1
239000003626 gastrointestinal polypeptide Substances 0.000 description 1
230000001330 gastroprokinetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
208000008384 ileus Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
IVNFTPCOZIGNAE-UHFFFAOYSA-N propan-2-yl hydrogen sulfate Chemical compound CC(C)OS(O)(=O)=O IVNFTPCOZIGNAE-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000010998 test method Methods 0.000 description 1
239000012085 test solution Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Macromonomer-Based Addition Polymer (AREA)

FI930051A 1992-01-07 1993-01-07 Menetelmä 4,13-dioksabisyklo[8.2.1]tridekenonijohdannaisten ja niiden välituotteiden valmistamiseksi FI106862B (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4200145		1992-01-07
DE4200145A DE4200145A1 (de)	1992-01-07	1992-01-07	7,10-epoxy-oxacyclododecan-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (3)

Publication Number	Publication Date
FI930051A0 FI930051A0 (fi)	1993-01-07
FI930051L FI930051L (fi)	1993-07-08
FI106862B true FI106862B (fi)	2001-04-30

Family

ID=6449136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI930051A FI106862B (fi)	1992-01-07	1993-01-07	Menetelmä 4,13-dioksabisyklo[8.2.1]tridekenonijohdannaisten ja niiden välituotteiden valmistamiseksi

Country Status (27)

Country	Link
US (1)	US5418224A (fr)
EP (1)	EP0550895B1 (fr)
JP (1)	JP3300084B2 (fr)
KR (1)	KR100273937B1 (fr)
CN (1)	CN1033646C (fr)
AT (1)	ATE155478T1 (fr)
AU (1)	AU667699B2 (fr)
CA (1)	CA2086811C (fr)
CZ (1)	CZ281773B6 (fr)
DE (2)	DE4200145A1 (fr)
DK (1)	DK0550895T3 (fr)
DZ (1)	DZ1652A1 (fr)
ES (1)	ES2104808T3 (fr)
FI (1)	FI106862B (fr)
GR (1)	GR3024859T3 (fr)
HU (2)	HU212272B (fr)
IL (1)	IL104158A (fr)
LT (1)	LT3015B (fr)
LV (1)	LV10458B (fr)
MX (1)	MX9300045A (fr)
NO (1)	NO179586C (fr)
PH (1)	PH30098A (fr)
RU (1)	RU2107070C1 (fr)
SK (1)	SK279251B6 (fr)
TW (1)	TW238308B (fr)
UA (1)	UA29393C2 (fr)
ZA (1)	ZA9339B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9610960A (pt) *	1995-10-13	1999-03-02	Neurosearch As	Derivados de 8-azabiciclo [3.2.1] oct -2- eno sua preparação e uso
US6077943A (en) *	1996-03-01	2000-06-20	Takeda Chemical Industries, Ltd.	Method of producing erythromycin derivative
AU2231097A (en) *	1996-03-01	1997-09-16	Kitasato Institute, The	Processes for the preparation of erythromycin derivatives
DE19644195A1 (de) *	1996-10-24	1998-04-30	Solvay Pharm Gmbh	10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19805822B4 (de) *	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en) *	1998-02-13	2000-12-26	Solvay Pharmaceuticals Gmbh	11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
HRP980496B1 (en) *	1998-09-10	2007-03-31	GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o.	New thilozine hydroxy derivatives and a process for the preparation thereof
KR20040066186A (ko) *	2000-08-17	2004-07-23	샤단호칭키타사토겐큐쇼	신규 슈도에리쓰로마이신 유도체
RU2248981C2 (ru) *	2000-09-01	2005-03-27	Чугаи Сейяку Кабусики Кайся	Способ получения и очистки производных эритромицина
DE50204789D1 (de) *	2001-05-10	2005-12-08	Solvay Pharm Gmbh	Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US20040067896A1 (en) *	2002-07-25	2004-04-08	The Kitasato Institute	Novel pseudoerythromycin derivatives
ES2338789T3 (es)	2003-06-18	2010-05-12	Tranzyme Pharma Inc.	Antagonistas macrociclicos del receptor de motilina.
US7582611B2 (en) *	2005-05-24	2009-09-01	Pfizer Inc.	Motilide compounds
NZ568763A (en) *	2005-12-08	2010-04-30	Pfizer	Method for demethylating the 3'-dimethylamino group of erythromycin compounds
CA2662897C (fr)	2006-09-11	2017-11-07	Tranzyme Pharma, Inc.	Antagonistes macrocycliques du recepteur de la motiline pour le traitement de troubles de dysmotilite gastro-intestinale
KR101120483B1 (ko) *	2006-12-05	2012-02-29	브리스톨-마이어즈 스퀴브 컴페니	모틸라이드 다형체
US20080287371A1 (en) *	2007-05-17	2008-11-20	Tranzyme Pharma Inc.	Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
EP2979702A4 (fr) *	2013-03-25	2016-11-16	Zeria Pharm Co Ltd	Agent gastrocinétique postprandial

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3725385A (en)	1970-11-02	1973-04-03	Abbott Lab	Process for the demethylation of 3-amino macrolides
US5106961A (en) *	1987-05-26	1992-04-21	Eli Lilly And Company	Erythromycin ring-contracted derivatives
CA1321581C (fr) *	1987-05-26	1993-08-24	Herbert A. Kirst	Macrolides contractes en anneaux
US4920102A (en) *	1988-04-18	1990-04-24	Eli Lilly And Company	Method for treating gastrointestinal disorders

1992
- 1992-01-07 DE DE4200145A patent/DE4200145A1/de not_active Withdrawn
- 1992-11-18 SK SK3414-92A patent/SK279251B6/sk unknown
- 1992-11-18 CZ CS923414A patent/CZ281773B6/cs not_active IP Right Cessation
- 1992-12-13 DZ DZ920162A patent/DZ1652A1/fr active
- 1992-12-18 IL IL104158A patent/IL104158A/xx not_active IP Right Cessation
- 1992-12-18 PH PH45475A patent/PH30098A/en unknown
- 1992-12-21 HU HU9204076A patent/HU212272B/hu not_active IP Right Cessation
- 1992-12-22 LT LTIP187A patent/LT3015B/lt not_active IP Right Cessation
- 1992-12-23 US US07/996,083 patent/US5418224A/en not_active Expired - Lifetime
- 1992-12-24 DE DE59208710T patent/DE59208710D1/de not_active Expired - Fee Related
- 1992-12-24 DK DK92122011.7T patent/DK0550895T3/da active
- 1992-12-24 ES ES92122011T patent/ES2104808T3/es not_active Expired - Lifetime
- 1992-12-24 AT AT92122011T patent/ATE155478T1/de not_active IP Right Cessation
- 1992-12-24 EP EP92122011A patent/EP0550895B1/fr not_active Expired - Lifetime
- 1992-12-28 KR KR1019920026335A patent/KR100273937B1/ko not_active Expired - Fee Related
- 1992-12-30 RU RU92016224A patent/RU2107070C1/ru not_active IP Right Cessation
1993
- 1993-01-05 ZA ZA9339A patent/ZA9339B/xx unknown
- 1993-01-06 NO NO930029A patent/NO179586C/no unknown
- 1993-01-06 CA CA002086811A patent/CA2086811C/fr not_active Expired - Fee Related
- 1993-01-06 JP JP00055793A patent/JP3300084B2/ja not_active Expired - Fee Related
- 1993-01-06 CN CN93100166A patent/CN1033646C/zh not_active Expired - Fee Related
- 1993-01-06 AU AU31036/93A patent/AU667699B2/en not_active Ceased
- 1993-01-06 LV LVP-93-01A patent/LV10458B/lv unknown
- 1993-01-07 MX MX9300045A patent/MX9300045A/es not_active IP Right Cessation
- 1993-01-07 FI FI930051A patent/FI106862B/fi active
- 1993-03-25 TW TW082102267A patent/TW238308B/zh active
- 1993-04-22 UA UA93002699A patent/UA29393C2/uk unknown
1994
- 1994-09-30 HU HU94P/P00031P patent/HU210216A9/hu unknown
1997
- 1997-09-24 GR GR970402503T patent/GR3024859T3/el unknown

Also Published As

Publication number	Publication date
NO930029D0 (no)	1993-01-06
AU667699B2 (en)	1996-04-04
MX9300045A (es)	1993-12-01
DZ1652A1 (fr)	2002-02-17
ZA9339B (en)	1993-08-05
TW238308B (fr)	1995-01-11
CZ281773B6 (cs)	1997-01-15
HUT66234A (en)	1994-10-28
SK341492A3 (en)	1995-05-10
NO179586B (no)	1996-07-29
HU210216A9 (en)	1995-02-28
JPH07247299A (ja)	1995-09-26
IL104158A0 (en)	1993-05-13
NO930029L (no)	1993-07-08
NO179586C (no)	1996-11-06
EP0550895A1 (fr)	1993-07-14
JP3300084B2 (ja)	2002-07-08
DE59208710D1 (de)	1997-08-21
IL104158A (en)	1997-07-13
US5418224A (en)	1995-05-23
RU2107070C1 (ru)	1998-03-20
KR100273937B1 (ko)	2000-12-15
KR930016436A (ko)	1993-08-26
CA2086811A1 (fr)	1993-07-08
LTIP187A (lt)	1994-03-25
DK0550895T3 (da)	1997-08-25
LV10458A (lv)	1995-02-20
LV10458B (en)	1996-02-20
DE4200145A1 (de)	1993-07-08
HU212272B (en)	1996-04-29
HU9204076D0 (en)	1993-04-28
FI930051L (fi)	1993-07-08
CA2086811C (fr)	2003-12-09
EP0550895B1 (fr)	1997-07-16
CZ341492A3 (en)	1993-07-14
LT3015B (lt)	1994-08-25
HK1014003A1 (en)	1999-09-17
AU3103693A (en)	1993-07-08
PH30098A (en)	1996-12-27
CN1033646C (zh)	1996-12-25
CN1075320A (zh)	1993-08-18
UA29393C2 (uk)	2000-11-15
ATE155478T1 (de)	1997-08-15
SK279251B6 (sk)	1998-08-05
FI930051A0 (fi)	1993-01-07
GR3024859T3 (en)	1998-01-30
ES2104808T3 (es)	1997-10-16

Publication	Publication Date	Title
FI106862B (fi)	2001-04-30	Menetelmä 4,13-dioksabisyklo[8.2.1]tridekenonijohdannaisten ja niiden välituotteiden valmistamiseksi
US5912235A (en)	1999-06-15	10, 13, 15-trioxatricyclo 9.2.1.1.9.6 !-pentadecan one derivatives, method for their production and pharmaceutical compositions containing them
MXPA97007974A (en)	1998-04-01	Derivatives of 10, 13, 15-trioxatriciclo [9.2.1.1 9.6] -pentadecanona, procedures for its preparation and medicines that contain these compounds
US6165985A (en)	2000-12-26	11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
KR100584017B1 (ko)	2006-05-30	11-아세틸-12,13-디옥사바이시클로〔8.2.1〕-트리데케논 유도체,이의 제조방법 및 이 화합물을 포함하는 약제
HK1014003B (en)	2000-06-23	4, 13-dioxabicyclo [8.2.1] tridecenone-derivatives, method and intermediates for their preparation, and medicaments containing the same
HK1010885B (en)	2003-03-14	10,13,15-trioxatricyclo [9.2.1.1.9.6]-pentadecanone-derivates, process for their preparation and pharmaceutical containing them
MXPA99001491A (en)	2000-04-24	Derivatives of 11-acetyl-12,13 dioxabiciclo [8.2.1] tridecenone, procedure for its preparation, and medications containing these compounds

Legal Events

Date	Code	Title	Description
1997-08-11	GB	Transfer or assigment of application	Owner name: SOLVAY PHARMACEUTICALS GMBH